146 related articles for article (PubMed ID: 29200164)
1. Neuropilin-1/CD304 Expression by Flow Cytometry in Pediatric Precursor B-Acute Lymphoblastic Leukemia: A Minimal Residual Disease and Potential Prognostic Marker.
Abaza HM; Alfeky MAA; Eissa DS; Abdel Fattah MF; Annaka LM; Ebeid FS
J Pediatr Hematol Oncol; 2018 Apr; 40(3):200-207. PubMed ID: 29200164
[TBL] [Abstract][Full Text] [Related]
2. CD304/neuropilin-1 is a very useful and dependable marker for the measurable residual disease assessment of B-cell precursor acute lymphoblastic leukemia.
Gudapati P; Khanka T; Chatterjee G; Ghogale S; Badrinath Y; Deshpande N; Patil J; Narula G; Shetty D; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
Cytometry B Clin Cytom; 2020 Jul; 98(4):328-335. PubMed ID: 31944572
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of CD73, CD86 and CD304 in normal vs. leukemic B-cell precursors and their utility as stable minimal residual disease markers in childhood B-cell precursor acute lymphoblastic leukemia.
Sędek Ł; Theunissen P; Sobral da Costa E; van der Sluijs-Gelling A; Mejstrikova E; Gaipa G; Sonsala A; Twardoch M; Oliveira E; Novakova M; Buracchi C; van Dongen JJM; Orfao A; van der Velden VHJ; Szczepański T;
J Immunol Methods; 2019 Dec; 475():112429. PubMed ID: 29530508
[TBL] [Abstract][Full Text] [Related]
4. CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry.
Solly F; Angelot F; Garand R; Ferrand C; Seillès E; Schillinger F; Decobecq A; Billot M; Larosa F; Plouvier E; Deconinck E; Legrand F; Saas P; Rohrlich PS; Garnache-Ottou F
Cytometry A; 2012 Jan; 81(1):17-24. PubMed ID: 22052678
[TBL] [Abstract][Full Text] [Related]
5. Expression of CD304/neuropilin-1 in adult b-cell lymphoblastic leukemia/lymphoma and its utility for the measurable residual disease assessment.
Chatterjee G; Dudakia V; Ghogale S; Deshpande N; Girase K; Chaturvedi A; Shetty D; Senger M; Jain H; Bagal B; Bonda A; Punatar S; Gokarn A; Khattry N; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
Int J Lab Hematol; 2021 Oct; 43(5):990-999. PubMed ID: 33432783
[TBL] [Abstract][Full Text] [Related]
6. NRP-1/CD304 expression in acute leukemia: a potential marker for minimal residual disease detection in precursor B-cell acute lymphoblastic leukemia.
Meyerson HJ; Blidaru G; Edinger A; Osei E; Schweitzer K; Fu P; Ho L
Am J Clin Pathol; 2012 Jan; 137(1):39-50. PubMed ID: 22180477
[TBL] [Abstract][Full Text] [Related]
7. Flow-cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric B-cell precursor acute lymphoblastic leukemia in trial AIEOP-BFM-ALL 2000.
Schumich A; Maurer-Granofszky M; Attarbaschi A; Pötschger U; Buldini B; Gaipa G; Karawajew L; Printz D; Ratei R; Conter V; Schrappe M; Mann G; Basso G; Dworzak MN;
Pediatr Blood Cancer; 2019 May; 66(5):e27590. PubMed ID: 30561169
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of diagnostic efficacy of NRP-1/CD304 in hematological diseases.
Liu YJ; Li XH; Song YL; Zhou YC; Cai RZ; Chi PD
Cancer Med; 2023 May; 12(10):11284-11292. PubMed ID: 36965095
[TBL] [Abstract][Full Text] [Related]
9. TEL-AML1 fusion RNA as a new target to detect minimal residual disease in pediatric B-cell precursor acute lymphoblastic leukemia.
Cayuela JM; Baruchel A; Orange C; Madani A; Auclerc MF; Daniel MT; Schaison G; Sigaux F
Blood; 1996 Jul; 88(1):302-8. PubMed ID: 8704188
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000.
Tembhare PR; Ghogale S; Ghatwai N; Badrinath Y; Kunder N; Patkar NV; Bibi AR; Chatterjee G; Arora B; Narula G; Banawali S; Deshpande N; Amare P; Gujral S; Subramanian PG
Cytometry B Clin Cytom; 2018 Jan; 94(1):100-111. PubMed ID: 27718302
[TBL] [Abstract][Full Text] [Related]
11. Role of CD81 and CD58 in minimal residual disease detection in pediatric B lymphoblastic leukemia.
Tsitsikov E; Harris MH; Silverman LB; Sallan SE; Weinberg OK
Int J Lab Hematol; 2018 Jun; 40(3):343-351. PubMed ID: 29500862
[TBL] [Abstract][Full Text] [Related]
12. The Evolving Landscape of Flowcytometric Minimal Residual Disease Monitoring in B-Cell Precursor Acute Lymphoblastic Leukemia.
Verbeek MWC; van der Velden VHJ
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732101
[TBL] [Abstract][Full Text] [Related]
13. Detection of minimal residual disease in childhood B-acute lymphoblastic leukemia by 4-color flowcytometry.
Baraka A; Sherief LM; Kamal NM; Shorbagy SE
Int J Hematol; 2017 Jun; 105(6):784-791. PubMed ID: 28324281
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: potential usefulness in minimal residual disease detection.
DiGiuseppe JA; Fuller SG; Borowitz MJ
Cytometry B Clin Cytom; 2009 Mar; 76(2):150-5. PubMed ID: 18831072
[TBL] [Abstract][Full Text] [Related]
15. A High-Sensitivity 10-Color Flow Cytometric Minimal Residual Disease Assay in B-Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2-in-10
Tembhare PR; Subramanian Pg PG; Ghogale S; Chatterjee G; Patkar NV; Gupta A; Shukla R; Badrinath Y; Deshpande N; Narula G; Rodrigues P; Girase K; Dhaliwal D; Prasad M; Shetty D; Banavali S; Gujral S
Cytometry B Clin Cytom; 2020 Jan; 98(1):57-67. PubMed ID: 31197916
[TBL] [Abstract][Full Text] [Related]
16. B Lymphoblastic Leukemia Minimal Residual Disease Assessment by Flow Cytometric Analysis.
Shaver AC; Seegmiller AC
Clin Lab Med; 2017 Dec; 37(4):771-785. PubMed ID: 29128068
[TBL] [Abstract][Full Text] [Related]
17. Aberrant underexpression of CD81 in precursor B-cell acute lymphoblastic leukemia: utility in detection of minimal residual disease by flow cytometry.
Muzzafar T; Medeiros LJ; Wang SA; Brahmandam A; Thomas DA; Jorgensen JL
Am J Clin Pathol; 2009 Nov; 132(5):692-8. PubMed ID: 19846809
[TBL] [Abstract][Full Text] [Related]
18. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry.
Thörn I; Forestier E; Botling J; Thuresson B; Wasslavik C; Björklund E; Li A; Lindström-Eriksson E; Malec M; Grönlund E; Torikka K; Heldrup J; Abrahamsson J; Behrendtz M; Söderhäll S; Jacobsson S; Olofsson T; Porwit A; Lönnerholm G; Rosenquist R; Sundström C
Br J Haematol; 2011 Mar; 152(6):743-53. PubMed ID: 21250970
[TBL] [Abstract][Full Text] [Related]
19. Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: method and significance.
Dworzak MN; Fritsch G; Panzer-Grümayer ER; Mann G; Gadner H
Leuk Lymphoma; 2000 Jul; 38(3-4):295-308. PubMed ID: 10830736
[TBL] [Abstract][Full Text] [Related]
20. Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study.
Borowitz MJ; Pullen DJ; Shuster JJ; Viswanatha D; Montgomery K; Willman CL; Camitta B;
Leukemia; 2003 Aug; 17(8):1566-72. PubMed ID: 12886244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]